期刊
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL
卷 20, 期 5, 页码 416-425出版社
ELSEVIER
DOI: 10.1016/j.hbpd.2021.06.009
关键词
Nonalcoholic steatohepatitis; Hepatitis B; NASH resolution; Antiviral treatment; Weight management
资金
- National Ma-jor Special Project for the Prevention and Treatment of Major Infectious Diseases: AIDS and viral hepatitis [2013ZX10005002, 2018ZX10725506]
- National Key Research and Development Program [2017YFC0908903]
This study investigated the outcomes of nonalcoholic steatohepatitis (NASH) in chronic hepatitis B (CHB) patients receiving antiviral treatment, revealing that lower BMI and weight reduction positively affected NASH resolution, while virologic factors were not correlated with NASH resolution. The value of weight management in CHB patients during antiviral treatment warrants further evaluation.
Background: Although concomitant nonalcoholic steatohepatitis (NASH) is common in chronic hepatitis B (CHB), the impact of viral factors on NASH and the outcome of CHB patients concomitant with NASH remain unclear. We aimed to investigate the outcomes of NASH in CHB patients receiving antiviral treatment. Methods: In the post-hoc analysis of a multicenter trial, naive CHB patients receiving 72-week entecavir treatment were enrolled. We evaluated the biochemical, viral and histopathological responses of these patients. The histopathological features of NASH were also evaluated, using paired liver biopsies at baseline and week 72. Results: A total of 1000 CHB patients were finally enrolled for analysis, with 18.2% of whom fulfilling the criteria of NASH. A total of 727 patients completed entecavir antiviral treatment and received the second biopsy. Serum HBeAg loss, HBeAg seroconversion and HBV-DNA undetectable rates were similar between patients with or without NASH (P > 0.05). Among patients with NASH, the hepatic steatosis, ballooning, lobular inflammation scores and fibrosis stages all improved during follow-up (all P < 0.001), 46% (63/136) achieved NASH resolution. Patients with baseline body mass index (BMI) >= 23 kg/m(2) (Asian criteria) [odds ratio (OR): 0.414; 95% confidence interval (95% CI): 0.190-0.899; P = 0.012] and weight gain (OR: 0.187; 95% CI: 0.050-0.693; P = 0.026) were less likely to have NASH resolution. Among patients without NASH at baseline, 22 (3.7%) developed NASH. Baseline BMI >= 23 kg/m(2) (OR: 12.506; 95% CI: 2.813-55.606; P = 0.001) and weight gain (OR: 5.126; 95% CI: 1.674-15.694; P = 0.005) were predictors of incident NASH. Conclusions: Lower BMI and weight reduction but not virologic factors determine NASH resolution in CHB. The value of weight management in CHB patients during antiviral treatment deserves further evaluation. (C) 2021 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据